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NucleusWe have identiﬁed a conserved nuclear pore localisation signal (NPLS; amino acids 764–838 of EPAC1) in the
catalytic domains of the cAMP-sensors, EPAC1 and EPAC2A. Consequently, EPAC1 is mainly localised to the nuclear
pore complex in HEK293T cells where it becomes activated following stimulationwith cAMP. In contrast, structural
models indicate that the cAMP-binding domain of EPAC2A (CNBD1) blocks access to the conservedNPLS in EPAC2A,
reducing its ability to interact with nuclear binding sites. Consequently, a naturally occurring EPAC2 isoform,
EPAC2B, which lacks CNBD1 is enriched in nuclear fractions, similar to EPAC1. Structural differences in EPAC iso-
forms may therefore determine their intracellular location and their response to elevations in intracellular cAMP.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Cyclic adenosine monophosphate (cAMP) signalling is initiated in
response to Gs-coupled protein receptor (GPCR) activation at the cell
membrane. The subsequent dissociation of G-protein alpha subunits
leads to adenylate cyclase (AC) activation. The conversion of ADP to
cAMP by AC leads to a rise in intracellular cAMP and activation of the ef-
fector proteins, protein kinase A (PKA), exchange proteins activated by
cAMP (EPAC) and cyclic nucleotide gated ion channels. The cAMP signal
is terminated by the cAMP phosphodiesterase (PDE) family [1], which
catalyses the conversion of cAMP into 5′-AMP. The intracellular
localisation of PDEs allows the formation of distinct subcellular pools
of cAMP, which selectively activates co-distributed EPAC and PKA mol-
ecules. Therefore, cAMP signalling is not only regulated by the induction
and depletion of the cAMP signal, but also by the localisation of effector
molecules [2].
The compartmentalisation of PKA activity has been extensively stud-
ied [3–5], but the effects of EPAC localisation on cAMP signalling are
only beginning to be appreciated. EPAC proteins are a family of cAMP-
activated guanine nucleotide exchange factors (GEFs) for the small
Ras-like GTPases, Rap1 and Rap2 [6,7]. The ﬁrst clues that indicated a
role for compartmentalisation in the regulation of EPAC signalling
arose during the study of its redistribution during the cell cycle. During
interphase EPAC1 was observed to adopt a perinuclear distribution [8]AMP; GEF, guanine nucleotide
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. This is an open access article underand, as the cell cycle progressed, EPAC underwent translocation,
co-localising with microtubules, the mitotic spindle and the contractile
ring [8]. Subsequently, functional importance has been ascribed to the
direct interaction of EPAC1 with microtubules [9] and microtubule
accessory proteins [10–13]. EPAC1 has been shown to stabilise microtu-
bule polymerisation [9] and promote actin stability within vascular
endothelial cells (VECs) [12,14]. Thus the distribution of EPAC within
the cell appears to strongly correlate with the nature of the cellular
effects induced in response to cAMP.
Three EPAC isoforms, EPAC1, EPAC2A and EPAC2B display different
cellular distributions, tissue expression and physiological roles in
humans [15]. Recent studies have focused on the nuclear localisation
of EPAC1, which occurs during interphase [8,16–19]. Nuclear
localisation is mediated by an interaction between the zinc ﬁnger do-
main of the nuclear pore protein RanBP2 (Ran Binding Protein 2) and
the catalytic domain of EPAC1 [17]. Interestingly, this interaction limits
the GEF activity of EPAC1, suggesting that complex formation may
negatively regulate EPAC activity within the cell. Given the growing ap-
preciation that compartmentalisation of EPAC proteins controls their
function and activity;we aimhere to investigate the structural elements
in EPAC isoforms that facilitate their recruitment to the nuclear
membrane.
2. Materials and methods
2.1. Materials
Forskolin and rolipramwere purchased fromMillipore, Hertfordshire,
UK. RedDot nuclear stain was purchased from Cambridge Biosci-
ence, Cambridge, UK. Protein A/G beads were from GE Healthcare,
Buckinghamshire, UK.the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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pFlag-CMV2-EPAC2A and pFlag-CMV2-EPAC2B were kind gifts from
Professor Susumu Seino, Kobe University, Japan [15]. pMT2-HA-EPAC1
and pMT2-HA-EPAC2 were generously provided by Professor Johannes
Bos, University of Utrecht, Netherlands [6,20]. Generation of pFlag-
CMV2-EPAC1-620–881, pFlag-CMV2-EPAC1-691–881, pFlag-CMV2-
EPAC1-764–881, and pFlag-CMV2-EPAC1-838–881 has been described
previously [10].
2.3. Mutagenesis
Site directedmutagenesis was done using the QuikchangeMutagen-
esis kit from Agilent. pFlag-CMV2-EPAC1 was mutated to pFlag-CMV2-
EPAC1-R805N-A806T-M809T (Area1, F-GATGAGAATGATGGCCGACACC
GCGCGGACCCTGCACCACTGCCG, R-CGGCAGTGGTGCAGGGTCCGCGCG
GTGTCGGCCATCATTCTCATC), pFlag-CMV2-EPAC1-Δ824–844 (Area2, F-
CGAGTTTCCCACCTCCCAGCCAGCACCTGGG, R-GCCCAGGTGCTGGCTGGG
AGGTGGGAAACTCG), pFlag-CMV2-EPAC1-Δ764–838 (F-CGACTGGCCA
GGATTTCCACATGC, R GCATGTGGAAATCCTGGCGAGGGCCAGTCG) and
pFlag-CMV2-EPAC1-P819A-P821A-P824A (3P-A, F-GCCGAAGCCACAAC
GCGGTGGCGCTCTCAGCGCTCAGAAGCCGAGTTTCC, R-GGAAACTCGGCT
TCTGAGCGCTGAGAGCGCCACCGCGTTGTGGCTTCGGC), respectively.
2.4. Antibodies
Anti-EPAC1 (Clone 5D3), phospho-CREB (Ser 133) and normal rab-
bit IgG were from New England Biolabs (Ipswich, UK). Anti-Ran GTPase
was purchased from BD signal Transduction, Oxford, UK. Anti-RanBP2
(#2938 for western blot analysis and #6429 for immunoﬂuorescent de-
tection)was purchased fromAbcam, Cambridge, UK. Anti-HA, Anti-Flag
(cloneM2) and normalmouse IgGwere from SigmaAldrich, Dorset, UK.
Alexa-Fluor secondary antibodies anti-rabbit/anti-mouse 488 nm and
568 nm were purchased from Invitrogen, Paisley, UK. Near-Infrared
(IR) secondary antibodies were from Licor Biosciences (Nebraska,
USA; anti-rabbit/anti-mouse 680 nm and 700 nm).
2.5. Cell culture
Stably transfected Human Embryonic Kidney (HEK293T) cells,
expressing either 3xFlag-myc-CMV-26 vector (Sigma-Aldrich, UK)
containing full-length human EPAC1 or vector alone, were prepared
by Dundee Cell Products (Dundee, UK). HEK293T cells were grown in
Dulbecco's modiﬁed Eagle's medium (DMEM) 10% (v/v) foetal bovine
serum (Sigma-Aldrich, UK), 2% (v/v) glutamine (Sigma-Aldrich, UK)
and 2% (v/v) penicillin/streptomycin (Sigma-Aldrich, UK) and
incubated at 37 °C in 5% (v/v) CO2. Selection of stable cell lines was
maintained by addition of 400 mg/ml G418 (Sigma-Aldrich, UK) to
growth medium.
2.6. Immunoﬂuorescent confocal microscopy
Cells were seeded at a density of 1 × 105 on ethanol sterilised 13mm
glass coverslips and allowed to adhere overnight. Cells were then
transfected using Lipofectamine 2000 transfection reagent (Invitrogen),
according tomanufacturer's guidelines. Cells were then stimulatedwith
indicated treatments prior to ﬁxationwith Fixing Buffer (3% (w/v) para-
formaldehyde, 1% (w/v) sucrose, 1 mM CaCl2, 1 mM MgCl2 in PBS
(37 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, 1.46 mM KH2PO4,
pH 7.4)). Coverslips were then quenched for 10 min in 50 mM NH4Cl
in PBS, permeabilised for 4 min with 0.1% (v/v) Triton X-100 in PBS.
Cells were blocked with 0.02% (v/v) goat serum in 0.02% (w/v) ﬁsh
skin gelatine in PBS, ﬁltered (0.2 μm Nalgene vacuum ﬁlter). Primary
and secondary antibodies (anti-mouse/anti-rabbit FITC/Rhodamine
conjugates or Rhodamine-Phalloidin in actin stained cells) were then
incubated for 1 h at room temperature (RT) sequentially beforetreatment with 4′, 6-diamidino-2-phenylindole (DAPI, 10 μg/ml) for
20 min at room temperature. Coverslips were washed in 3× in Block
buffer between incubations. Coverslips were then mounted onto glass
slides using Shandon Immuno-Mount (Thermo Fisher Scientiﬁc, UK)
and analysed using a 63X Zeiss oil immersion objective, on a Zeiss
confocal microscope (Carl Zeiss, Germany) equipped with a Zeiss
LSM5 Pascal instrument.
2.7. Immunoprecipitation
Cells were grown to 90% conﬂuency and then lysed in immunopre-
cipitation (IP) buffer Hepes pH 7.4, 150 mM NaCl, 5 mM EDTA, 1 mM
NaF, 10mMNaPO4, 1% (w/v) Triton X-100 plus protease inhibitor cock-
tail (Roche). Following lysis, cell debris was removed by centrifugation
(10,000 rpm, 10 min). Lysates were then pre cleared with normal
mouse IgG and IP carried out with anti-EPAC1 (5D3) or anti-Flag anti-
bodies and then incubated with protein A or protein G beads, respec-
tively, for 1 h (4 °C, rotating). Beads were collected and washed 3
times and then boiled in electrophoresis buffer (63 mM Tris–HCl, 10%
(v/v) glycerol, 2% (w/v) SDS, 0.0025% (w/v) bromophenol blue). Cell
lysates and IP samples were analysed by western blotting.
2.8. Fractionation and western blotting
Cells were fractionated using a nuclear fractionation kit (Active
Motif) into cytoplasmic and nuclear components. Equal amounts of
lysate protein were then separated on 7% and 12% (w/v) SDS PAGE
gels, transferred to nitrocellulose membranes and then incubated with
shaking for 1 h in block buffer (1% (w/v) skimmed milk powder in
TBST (50mMTris; 150mMNaCl; 0.05% Tween 20)). Primary antibodies
were incubated at 4 °C overnight followed by incubation with infrared
secondary conjugated antibodies for 1 h at RT. Infrared secondary anti-
bodies were visualised using the the ODYSSEY® Sa Infrared Imaging
System (Licor Biosciences, Nebraska, USA).
2.9. Structural analysis
Multiple alignment of EPAC1 and EPAC2 sequences (UniProt) and
structural analyses were carried out using Jalview [21], Muscle align-
ment server [22] and PyMOL [23]. Homology models of EPAC1 and
EPAC2B were made using Modeller V9.14 [24]. EPAC1 and EPAC2B se-
quences (UniProt accession numbers, 095398 and A2ASW8, respective-
ly) were aligned with and modelled on EPAC2A (closed conformation,
structure 2BYV, [25]) and models with lowest DOPE scores chosen.
3. Results
3.1. EPAC1 is activated at the nuclei of HEK293T cells following cAMP
stimulation
The subcellular distribution of Flag-tagged EPAC1was determined in
transfected HEK293T cells by immunoﬂuorescent staining with the
anti-EPAC1 (5D3) antibody from New England Biolabs. Anti-EPAC1
(5D3) has been reported to preferentially interact with EPAC1 in the ac-
tive, cAMP-bound state as its epitope lies within the cyclic nucleotide
binding domain (CNBD) of EPAC1 [26]. We found that anti-EPAC1
(5D3) was able to detect EPAC1 protein in cells expressing EPAC1, but
not in the control cell transfectedwith vector alone. However, elevation
of intracellular cAMP, induced by treatment of cells with a combination
of the adenylate cyclase activator, forskolin, and the type 4 PDE inhibi-
tor, rolipram, (F/R) led to increased EPAC1 immunoﬂuorescence within
the nuclei of transfected cells (Fig. la). In order to assess the importance
of cAMP binding and activation on the nuclear staining of EPAC1, cells
were transiently transfected with a mutant form of EPAC1 (EPAC1-
R279E), which is deﬁcient in cAMP binding (Fig. 1b). Consequently,
EPAC1-R279E immunostaining was unaffected by elevations in
Fig. 1. Active EPAC1 is localised to the nucleus in HEK293T cells.
a) HEK293T stably expressing either empty vector or EPAC1-FLAG construct was treated with or without a combination of forskolin and rolipram (F/R, 10 μM, 60′). Cells were ﬁxed for
immunoﬂuorescence using anti-EPAC1 (5D3) antibodies.
b) HEK293T cells were transiently transfected with either wild type EPAC1 or EPAC1-R279E constructs and then incubated with F/R (10 μM, 60′), followed by immuno-detection with
anti-EPAC1 (5D3).
c) Immunoprecipitation of EPAC1 from stably transfected HEK293T cells. Cell lysates (input) were immunoprecipitatedwith anti-IgG (mouse), anti-EPAC1 (5D3) or anti-FLAG antibod-
ies (square indicates lane moved for ease of presentation).
d) HEK293T cells were transiently transfectedwith a EPAC1-HA construct. Cells were then treatedwith F/R (10 μM, 60′),ﬁxed and probed using anti-EPAC1 (5D3) or anti-HA antibodies
as indicated.
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speciﬁcally recognises active, cAMP-bound EPAC1 in the nuclei of
HEK293T cells.
To conﬁrm that the anti-EPAC1 (5D3) speciﬁcally recognises the ac-
tive formof EPAC1, immunoprecipitation (IP) experimentswere carried
out on cells transfected with FLAG-tagged EPAC1 (EPAC1-FLAG) using
the anti-EPAC1 (5D3) antibody (Fig. 1c). Results demonstrated that
more EPAC1-FLAG protein was precipitated using the anti-EPAC1
(5D3) antibody, following F/R stimulation, whereas anti-FLAG IP of
EPAC1 was unaffected by elevations in intracellular cAMP (Fig. 1c).
This conﬁrms that the anti-EPAC1 (5D3) antibody speciﬁcally recog-
nises the active form of EPAC1 in the nuclei of F/R-stimulated
HEK293T cells.
To assesswhether EPAC1 translocates to thenucleus following cAMP
stimulation, we next compared the subcellular distribution of HA-
tagged EPAC1 (EPAC1-HA) in transfected HEK293T cells, using anti-
EPAC1 (5D3) and anti-HA antibodies (Fig. 1d). Immuno-staining of
transfected cells with anti-HA antibodies revealed a distinct perinuclear
distribution of EPAC1 (Fig. 1d), which is in agreement with published
results [17]. Furthermore, F/R stimulation did not alter the distribution
of EPAC1 distribution when probed with an anti-HA antibody, indicat-
ing that nuclear EPAC1 protein levels remain constant following stimu-
lationwith cAMP. Together these results demonstrate that EPAC1 is pre-
localised to the nucleus in HEK293T cells, where it becomes activated
following elevations of intracellular cAMP.3.2. EPAC1 and EPAC2A are localised to distinct subcellular compartments
EPAC1 and EPAC2A have been reported to occupy distinct subcellu-
lar compartments, whereby EPAC1 displays a mainly perinuclear distri-
bution during interphase [8,16–19] and EPAC2A is largely cytoplasmic
[15,27]. We therefore compared the subcellular distribution of EPAC
isoforms in HEK293T cells by transfecting cells with EPAC1-HA or
EPAC2A-HA constructs and observing their subcellular distribution
using immunoﬂuorescent confocal microscopy (Fig. 2a). In agreement
with previous studies, EPAC1was observed to accumulate at the nuclear
membrane,whereas EPAC2Awas evenly distributed throughout the cell
[17,27]. Furthermore, co-staining of EPAC1 with the nuclear pore pro-
tein RanBP2 revealed a strong level of co-localisation between EPAC1
and the nuclear pore complex (Fig. 2a, inset). This co-localisation was
not observed in EPAC2A transfected cells.
In order to conﬁrm the nuclear distribution of EPAC1, transfected
cells were fractionated into nuclear and cytoplasmic components. The
ﬁdelity of nuclear preparations was conﬁrmed by immunoblotting for
the nuclear pore protein, RanBP2, which is present in nuclear, but not
cytosolic fractions (Fig. 2b). Immunoblotting with anti-Ran GTPase
demonstrated equal protein loading of nuclear and cytosolic fractions
(Fig. 2b). Antibodies towards active, phosphorylated form of the PKA
substrate, CREB (Ser 133), were used to demonstrate that F/R treatment
promoted and increase in intracellular cAMP. Detection of EPAC1 and
EPAC2A within each fraction conﬁrmed the protein distributions
a) b)
c)
Fig. 2. EPAC isoforms display differential targeting in HEK293T cells.
a) The subcellular distribution of EPAC1-HA and EPAC2A-HA in HEK293T by immunostaining with anti-HA antibodies. EPAC-HA proteins are stained green, the nuclear pore protein,
RanBP2, is stained red and the Reddot nuclear stain is white. Merged images are also shown (EPAC1/RanBP2 colocalisation—yellow). Inset indicates the strong colocalisation of
EPAC1 with RanBP2 at the nuclear membrane.
b) HEK293 cells were stimulated in the presence or absence of F/R (10 μM, 1 h) and then fractionated into nuclear and cytoplasmic fractions, which were immunoblotted with the
indicated antibodies.
c) Accumulation of transfected EPAC proteins in the nuclear fraction was assessed by densitometric analysis (n-3, ±s.e.m.). **P b 0.01 (two way ANOVA).
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EPAC1 was enriched with the nuclear pore protein RanBP2 within
nuclear fractions, whereas EPAC2A was enriched in the cytoplasmic
fraction (Fig. 2b). Densitrometric analysis of immunoblots revealed
that 68% (±8%) of total cellular EPAC1 was found within the nuclear
fraction compared to only 40% (±8%) of EPAC2A (Fig. 2c). Similar to
the distribution of each isoform observed by microscopic analysis, F/R
stimulation had no effect on the distribution of either isoform. It is inter-
esting to note that the distribution of both EPAC1 and EPAC2A was not
affected by F/R stimulation (Fig. 2b), despite earlier reports of EPAC1
[17] and EPAC2A [27] translocations in response to cAMP.
3.3. The catalytic domain of EPAC1 is required for nuclear localisation
Nuclear accumulation of EPAC1 [10] and interaction with RanBP2
[17] both rely on the catalytic CDC25 Homology Domain (CDC25-HD)
of EPAC1, however the precise region within this domain has not
been determined. We therefore examined the nuclear localisation of a
range of truncated EPAC1 mutants in transfected HEK293T cells
(Fig. 3). As previously reported [10,17] deletion of the N-terminal regu-
latory domain of EPAC1 to the CDC25HD(EPAC1 620–881) had no effect
on nuclear accumulation, indicating that theN-terminus of EPAC1 is dis-
pensable for nuclear targeting (Fig. 3a). In order to ascertain the region
required for nuclear targeting, the CDC25-HD was further truncated by
70 amino acid increments yielding EPAC1 691–881, 764–881 and 838–
881. Both EPAC1 691–881 and EPAC1 764–881 displayed a similar
distribution to wild type EPAC1 within the nuclear fraction (Fig. 3a).
However, in agreement with our previous observations in COS1 cells[10], EPAC1 838–881 was observed to signiﬁcantly accumulate within
the cytoplasmic fraction, suggesting that nuclear localisation may re-
quire amino acids 764–838 (Fig. 3a and b). In order to conﬁrm the im-
portance of these residues in nuclear targeting, amino acids 764–838
were deleted from full length EPAC1. Fractionation of cell extracts
from EPAC1WT and EPAC1 Δ764–838-transfected cells revealed signif-
icantly higher levels of cytosolic EPAC1 Δ764–838 compared to wild
type protein (Fig. 3c and d), suggesting that these residues are involved
in the nuclear localisation of EPAC1. Moreover, immunoﬂuorescent
staining demonstrated that EPAC1 Δ764–838 failed to accumulate at
the perinuclear domain and adopted a cytosolic distribution in contrast
to full length protein (Fig. 3e). Cell fractionation and immunoﬂuores-
cent detection together implicate amino acids 764–838 as being vital
for determining the subcellular distribution of EPAC1 and therefore
represents a novel nuclear pore localisation signal (NPLS) in EPAC1.
3.4. EPAC1 and EPAC2 share a conserved nuclear pore targeting signal
Control over nuclear targeting of EPAC1 has been linked to a direct
interaction between the EPAC1 CDC25-HD and RanBP2 [17]. Our work
identiﬁes a region within the CDC25-HD that is involved in nuclear
targeting (Fig. 3). Since EPAC1 is targeted to the nucleus by this NPLS,
whereas EPAC2A is not (Fig. 3), regions of low sequence similarity with-
in the NPLSmay reveal structural differences that underlie the differen-
tial targeting of EPAC1 and EPAC2A. We therefore aligned the primary
sequence of EPAC1 764–851 with the corresponding region of EPAC2A
(amino acids 915–979). The CDC25-HD and the NPLS are intimately
involved in GEF activity and interactions with Rap GTPase and as such
993E. Parnell et al. / Cellular Signalling 27 (2015) 989–996EPAC1 and EPAC2A share a considerable sequence similarity within this
region (Fig. 4a). However, two regions of lowsequence similarity, dubbed
Area1 and Area2, were identiﬁed that may underlie the differences ina)
e)
c)
Fig. 3. Identiﬁcation of a nuclear pore targeting signal (NPLS) in EPAC1.
a) Fractionation and western blotting of cytoplasmic and nuclear extracts from HEK293T c
620–881 is the full CDC25-HD and 691–881, 764–881 and 838–881 represent further trun
b) Quantiﬁcation of the relative distribution of transfected EPAC1 mutants in nuclear fraction
c) Western blot analysis of cytoplasmic and nuclear fractions of HEK293T cells transfected w
d) Band intensity was calculated and the percentage of each mutant within the nuclear fract
e) HEK293T cells were transfected with EPAC1-WT or EPAC1 Δ764–838 and then immunost
brane was labelled with the anti-RanBP2 antibody (red) and the nucleus highlighted usinlocalisation observed between EPAC1 and EPAC2A (Fig. 4a). In addition
to low sequence similarity, both sites were determined to be available
for protein–protein interaction by their exposure to solvent (based onb)
d)
ells transiently transfected with truncated EPAC1 mutants. EPAC FL—full length EPAC1
cations through the CDC25-HD.
s (n = 3, ±s.e.m.). ***P b 0.001 (ANOVA).
ith full length EPAC1 (WT) and mutant EPAC1 lacking amino acids 764–838 (Δ764–838)
ion is shown (n-3, ±s.e.m.) **p b 0.01 (ANOVA).
ained with an anti-FLAG antibody (green) to detect transfected EPAC1. The nuclear mem
g Reddot nuclear stain (white). Superimposed images reveal co-localisation (merge).,
.
-
994 E. Parnell et al. / Cellular Signalling 27 (2015) 989–996EPAC1 homologymodel, Fig. 4b). Area1 (composing residues R805, A806
and M809, EPAC1 nomenclature) is found within a groove between two
conserved alpha helices and may form a suitable site for protein interac-
tion (Fig. 4b). Area2 is a region of 20 amino acidswhich forms an extend-
ed loop that is absent in EPAC2A and sufﬁciently long to afford EPAC1 a
unique protein–protein interaction motif (Fig. 4b). As a result of their
low sequence similarity and availability for protein–protein interaction,
Area1 and Area2 represent good candidate regions involved in EPAC1
nuclear targeting.
In order to test the importance of Area1 and Area2, their amino acid
sequences were converted bymutagenesis to the corresponding region
of EPAC2A, i.e. Area 1 (R805N, A806T, and M809T) and Area 2 (Δ832–
851). As EPAC2A displays a mainly cytoplasmic distribution, mimicking
the sequence of EPAC2A within these regions may disrupt nuclear
localisation of EPAC1 while maintaining catalytic activity. In addition,
mutagenesis of a rigid loop between Area1 and Area2 was designed toFig. 4.Mutation of non-conserved regions within the EPAC1 NPLS has no effect on EPAC1 distr
a) Sequence alignment of EPAC1 (a.a. 764–851) and EPAC2 (a.a. 915–979) indicating residue
region is highly conserved with the exception of two regions also predicted to be surface
mutations (R805N, A806T and M809T) are indicated (red arrowheads) and residues delet
b) Homologymodelling of EPAC1 based on EPAC2 crystal structure (2byv) [25] shows the CD
Area2, with speciﬁc residues of EPAC1 shown (red). The effects of EPAC1mutagenesis on th
(purple, transparent).
c) HEK293T cells were transfected with full length EPAC1 or NPLS mutants designed to disr
accumulation of each mutant in the cytoplasmic or nuclear fractions.
d) Band intensity was calculated from western blots and the amount of nuclear EPAC1 was cdisrupt both the secondary structure and protein–protein interactions
within this region of EPAC1. Accordingly, EPAC1 P819A, P821A, P824A
(3P-A) releases the rigidity imparted by each proline residue which
may deﬁne the structure of the region between Area1 and Area2. Frac-
tionation of transfected HEK293T cells revealed that while Δ764–838
was enriched within the cytoplasmic fraction, Area1, Area2 and 3P-A
mutagenesis did not have any signiﬁcant effect on the subcellular distri-
bution of EPAC1 (Fig. 4c and d). These data suggest that the difference in
localisation observed between EPAC1 and EPAC2A is not due to interac-
tions involving Area1 or Area2 of the EPAC1 NPLS.3.5. CNBD1 of EPAC2 disrupts nuclear localisation
The NPLS of EPAC1 appears to be important for nuclear targeting of
EPAC1. However this region is strongly conserved in EPAC2A, whichibution.
s 764–838 (NPLS) and a.a. 839–851 which are absent in EPAC2, but present in EPAC1. This
exposed when mapped onto a homology model of EPAC1. The positions of Area1 poin
ed by Area2 mutagenesis (a.a. 832–851) are highlighted (red line).
C25-HD (green) and NPLS (Blue). Insets identify the potential interaction sites, Area1 and
e corresponding EPAC2A sequences are shown by superimposing the structure of EPAC2A
upt nuclear accumulation. Fractionation and immuno-detection of proteins revealed the
alculated as a percentage of total protein observed (n-3, ±s.e.m.). **p b 0.01 (ANOVA).t
995E. Parnell et al. / Cellular Signalling 27 (2015) 989–996has reduced nuclear targeting. This observation suggests that structural
differences between EPAC1 and EPAC2Amay underlie the differences in
the localisations observed. One major difference between the two
isoforms is the presence of a second, N-terminal CNBD (CNBD1) in
EPAC2A. Furthermore, CNBD1 has previously been implicated in the
subcellular targeting of EPAC2A [15]. Interestingly, a third, tissue specif-
ic isoform of EPAC has been recently identiﬁed in the adrenal glands
[15]. In this case, differential splicing of the EPAC2A gene results in the
loss of the additional N-terminal CNBD1, yielding a truncated form,
EPAC2B [15]. Interestingly, comparison of an EPAC2B homology model
and the crystal structure of EPAC2A (2BYV [25]) reveals that CNBD1
lies in close proximity to the N-terminal section of the NPLS in
EPAC2A (Fig. 5a). It is therefore possible that steric interference from
CNBD1 blocks access of potential nuclear localisation partners, such as
RanBP2, to theNPLS of EPAC2A, but not EPAC1 or EPAC2B. In order to as-
sess the importance of the CNBD1 of EPAC2A in nuclear localisation,
EPAC1, EPAC2A and EPAC2B were transfected into HEK293T and their
sub-cellular distributions assessed by nuclear fractionation (Fig. 5b). Re-
sults demonstrated that while EPAC2B was observed to accumulate
within the nuclear fraction, the full length EPAC2A constructwas largely
cytosolic. Interestingly, EPAC2Bwas observed to be distributed between
the nuclear and cytoplasmic fractions (approximately 50:50), similar to
EPAC1 (Fig. 5b, c). These data support the idea that CNBD1 is an impor-
tant factor in determining the subcellular distribution of EPAC2A.Fig. 5. EPAC2B is more enriched in nuclear fractions than EPAC2A.
a) Homology model of EPAC2B (based on sequence alignment of EPAC2B with EPAC2A, cr
superimposed (transparent) to highlight its proximity to the NPLS (purple).
b) HEK293T cells were transfected with FLAG-tagged EPAC1, EPAC2A or EPAC2B. Fractionati
nuclear fractions.
c) Quantitative densitometry and calculation of nuclear EPAC were carried out for each tran4. Discussion
Various reports have demonstrated localisation of EPAC1 and
EPAC2A to distinct subcellular locales [15,17,19,27]. Indeed, we have
conﬁrmed that EPAC1 is tethered to the nucleus in transfected
HEK293T cells, whereas EPAC2A is largely cytosolic (Fig. 1). We identi-
ﬁed a nuclear pore localisation signal (NPLS; amino acids 764–838)
within the catalytic domain of EPAC1 that appears to be responsible
for nuclear tethering. We propose here that the CNBD1 of EPAC2A
may block access to the corresponding NPLS of EPAC2A, reducing its
ability to interact with nuclear binding sites. Indeed, a naturally occur-
ring EPAC2 isoform lacking CNBD1, EPAC2B, exhibits signiﬁcant enrich-
ment within the nuclear fraction, similar to EPAC1. Our structural
models suggest that the reason for this is that the NPLSs of EPAC1 and
EPAC2B aremore exposed for protein–protein interactionswith nuclear
pore complex (NPC) proteins.
In this regard, it has previously been shown that RanBP2 interacts
directly with the CDC25-HD of EPAC1 to mediate its localisation to the
nuclear envelope [17]. We have, however, been unable to demonstrate
this interaction in our cell system (results not shown), which suggests
that interactions with other protein constituents of the NPC may facili-
tate EPAC1 recruitment in HEK293T cells. In support of this idea is our
observation that EPAC1becomes activated following elevations in intra-
cellular cAMP in HEK293T cells (Fig. 1), whereas previous work hasystal structure 2BYV) is shown (green). The additional N-terminal CNBD1 of EPAC2A is
on and immunoblotting revealed the distribution of each protein within the cytosolic and
sfected protein (n-3, ±s.e.m.). *p b 0.05 (ANOVA).
996 E. Parnell et al. / Cellular Signalling 27 (2015) 989–996shown that interactions with RanBP2 inhibit EPAC1 activity at the nu-
clear pore. This suggests that the interactions responsible for NPC re-
cruitment in HEK293T cells do not suppress EPAC1 activity and may
therefore exert novel regulatory control over the actions of nuclear
EPAC1. Nuclear tethering of EPAC1 may therefore determine its ability
to be activated by cAMP in a cell type-speciﬁc manner, dependent on
whether or not EPAC1 has access to interaction with RanBP2 or other
binding proteins that do not inhibit activity. This also suggests that in
the future, chemical modulators could be devised that speciﬁcally dis-
rupt nuclear targeting, and hence the activity of EPAC1 and EPAC2B,
without affecting the activity of EPAC2A. This type of isoform-speciﬁc
regulation might be important due the differential roles each isoform
are observed to play in vivo. For example, EPAC1 is the principal isoform
in vascular endothelial cells, where it mediates anti-inﬂammatory sig-
nalling [28], whereas EPAC2A is involved in incretin-stimulated insulin
secretion in pancreatic β-cells [29–31]. Therefore it may be possible to
design drugs to regulate speciﬁc EPAC actions in one tissue while spar-
ing another, thereby reducing the potential risk of side effects.
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